A phase I/randomised phase II trial of abiraterone acetate with or without RO5503781 in patients with metastatic castration resistant prostate cancer (mCRCP) who have not previously received docetaxel
Phase of Trial: Phase I/II
Latest Information Update: 11 Feb 2016
At a glance
- Drugs Idasanutlin (Primary) ; Abiraterone; Prednisolone
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms MAdCaP
- 07 Jun 2017 Biomarkers information updated
- 04 Nov 2015 Accrual to date is 7% according to United Kingdom Clinical Research Network record.
- 18 Sep 2015 Accrual to date is 6% according to United Kingdom Clinical Research Network record.